IMI’s RADAR-CNS project is evaluating how wearable devices and smartphone technology could be used to monitor major depressive disorder, epilepsy, and multiple sclerosis. The project has now launched studies in all three disease areas; the results will ultimately make it easier to predict and hopefully prevent relapses, thereby dramatically improving patients’ quality of life.
The IMI Stakeholder Forum 2018 will take place on Wednesday 24 October in Brussels, Belgium. The theme this year is ‘The value of cross-sectoral health research and innovation’, and discussions will focus on the added value of technology convergence to address complex health challenges, especially in those areas where there is huge public health need.
An Antimicrobial Resistance (AMR) Accelerator Programme is part of new IMI Calls for proposals, along with topics on brain disorders, immune-mediated diseases clinical trial design, medicines safety, and blockchain technologies.
Liquid biopsies can help to diagnose cancer in its early stages, and assist clinicians in monitoring the impact of treatment at any point. IMI's CANCER-ID project has validated a series of tests for cancer cells to help develop more effective methods of diagnosis and more personalised treatments for lung and breast cancer - two of the most frequent malignancies in Europe.
‘Radical collaboration’ where multinational companies work together and share data instead of keeping it secret is helping to change the model of the pharmaceutical industry and solve problems more quickly, according to Carlos Moedas, the EU’s commissioner for research, science and innovation, speaking at an IMI 10th anniversary event in Brussels on 27 June.
A new Antimicrobial Resistance (AMR) Accelerator Programme is part of new Calls for proposals under development at IMI. Other topics slated for inclusion in the Calls address brain disorders and immune-mediated diseases.
IMI's WEB-RADR project has developed a mobile app enabling patients and healthcare professionals to more easily report suspected adverse drug reactions. It has also analysed social media to assess drug safety. Both initiatives have shown potential for strengthening the monitoring of medicines.
IMI’s MARCAR project has identified potential biomarkers that could indicate how likely a drug is to cause cancer at an earlier stage of testing than is currently possible, which could save drug companies time and money – and lead to safer drugs reaching patients faster.
GETREAL developed new tools and resources for incorporating real-life data into drug development, which could increase confidence in new medicines and help to get them to patients more quickly. In an interview with the IMI Programme Office, project coordinator Elaine Irving of GlaxoSmithKline explains the main project achievements, and why they wouldn’t have been possible without IMI.
The Innovative Medicines Initiative (IMI) has launched its 100th project in the form of Hypo-RESOLVE, a 4 year, EUR 26.8 million project on diabetes. The project focuses on hypoglycaemia, which occurs when diabetes patients’ blood sugar levels become dangerously low. Despite its seriousness, little is known about hypoglycaemia; the goal of Hypo-RESOLVE is to change that.